



SmartPA Criteria Proposal

Drug/Drug Class:	Synagis Clinical Edit
First Implementation Date:	October 1, 2003
Proposed Date:	June 16, 2022
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: Ensure appropriate utilization and control of Synagis® (palivizumab) injection

Why Issue Selected: Synagis® (palivizumab) injection was FDA approved in June 1998 for the prevention of infection in high-risk pediatric patients due to respiratory syncytial virus (RSV), the most common cause of pneumonia and bronchiolitis in infancy and early childhood. Synagis is the first monoclonal antibody approved to provide passive immunity for an infectious disease. Severe RSV disease is the most common reason infants under 1 year of age are hospitalized in the United States. The American Academy of Pediatrics (AAP) recommends limiting the usage of Synagis to certain preterm infants and infants with certain chronic illnesses.

Synagis is typically reserved for use during the RSV Season (November through April); however, in March of 2021, the CDC began to note an increase in RSV infections out of the typical season and following a significant drop in RSV cases during the COVID-19 pandemic, beginning in April 2020. This atypical RSV season led the AAP to publish guidance in August of 2021 urging Synagis administration to eligible infants where RSV activity approaches the typical fall-winter season levels. MO HealthNet will continue to assess and review guidance for out-of-season Synagis administration and will evaluate the need for additional doses on a month-to-month basis, dependent on RSV virology.

Program-Specific Information:

Date Range FFS 7-01-2021 to 10-31-2021 (atypical RSV season)			
Drug	Claims	Spend	Avg Spend per Claim
SYNAGIS 50 MG/0.5 ML VIAL	345	\$599,214.00	\$1,736.85
SYNAGIS 100 MG/1 ML VIAL	624	\$2,023,551.14	\$3,242.87
Date Range FFS 11-01-2021 to 4-30-2022 (typical RSV Season)			
Drug	Claims	Spend	Avg Spend per Claim
SYNAGIS 50 MG/0.5 ML VIAL	731	\$1,327,325.11	\$1,815.76
SYNAGIS 100 MG/1 ML VIAL	1,358	\$4,354,398.61	\$3,206.48

Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit

Data Sources: Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Synagis® (palivizumab) injection
- Age range: All appropriate MO HealthNet participants ≤ 24 months of age

Approval Criteria

- Claim is during RSV Season (November through April) **AND**
- For prematurity:
 - Participant aged ≤ 12 months and born ≤ 28 weeks gestation **OR**
 - Participant aged ≤ 6 months and born between 29 and 32 weeks gestation **OR**
 - Participant aged ≤ 3 months and born between 32 and 35 weeks gestation **AND**
 - Enrolled in childcare **OR**
 - Has siblings that are < 5 years of age **OR**
- For chronic lung disease:
 - Participant aged < 12 months and born < 32 weeks gestation with chronic lung disease **AND**
 - required more than 21% oxygen for 28 days following birth **AND**
 - currently requiring medical therapy (oxygen on a continuous basis, bronchodilator, diuretic, corticosteroid or ventilator dependent) **OR**
 - Participant aged < 24 months and born < 32 weeks gestation with chronic lung disease **AND**
 - required more than 21% oxygen for 28 days following birth **AND**
 - required continued medical therapy throughout the past 6 months (oxygen on a continuous basis, bronchodilator, diuretic, corticosteroid or ventilator dependent) **OR**
- For congenital heart disease:
 - Participant aged ≤ 24 months with hemodynamically significant cyanotic and acyanotic congenital heart disease **AND**
 - Receiving medication to control CHF (digoxin, beta blockers, calcium channel blockers, ACE inhibitors, nitroglycerin, anti-coagulants, diuretics, or supplemental oxygen) **OR**
 - Moderate to severe pulmonary hypertension **OR**
 - Cyanotic heart disease **OR**
- For congenital abnormality of the airway or neuromuscular disease that impairs ability to clear secretions: Participant aged < 12 months **OR**
- For severe immunodeficiencies that may benefit from prophylaxis as determined by clinical consultant review: Participant aged ≤ 24 months

Denial Criteria

- Therapy will be denied if all approval criteria are not met
- Therapy exceeds 5 doses per RSV season

Required Documentation

Laboratory Results:
MedWatch Form:

Progress Notes:
Other:

Disposition of Edit

Denial: Exception code "0682" (Clinical Edit)
Rule Type: CE

Default Approval Period

Max of 5 doses per RSV season

References

- Synagis® (palivizumab) [package insert]. Stockholm, Sweden: Swedish Orphan Biovitrum AB (publ); November 2020.
- Clinical Pharmacology. Palivizumab – Synagis. Accessed May 16, 2022.
- American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. *Pediatrics*. 2014 Aug;134(2):e620-38. doi: 10.1542/peds.2014-1666. PMID: 25070304.
- IPD Analytics. Infectious Diseases: Respiratory Syncytial Virus (RSV). Accessed May 16, 2022.
- American Academy of Pediatrics. Updated Guidance: Use of Palivizumab Prophylaxis to Prevent Hospitalization From Severe Respiratory Syncytial Virus Infection During the 2021-2022 RSV Season. Last Updated December 17, 2021. [Updated Guidance: Use of Palivizumab Prophylaxis to Prevent Hospitalization From Severe Respiratory Syncytial Virus Infection During the 2021-2022 RSV Season \(aap.org\)](#)
- Centers for Disease Control and Prevention. Increased Interseasonal Respiratory Syncytial Virus (RSV) Activity in Parts of the Southern United States. June 10, 2021. [CDC-HAN-443-Increased-Interseasonal-RSV-Activity-06.10.21.pdf](#)